Summary

Ajanta Pharma Limited delivered an excellent performance for the fourth quarter and the full fiscal year ended March 31, 2026. For Q4 FY 2026, revenue from operations climbed 21% year-on-year to ₹1,422 crore, with Profit after Tax rising 18% to ₹267 crore. The full fiscal year 2026 witnessed revenue from operations increasing 17% to ₹5,453 crore, while Profit after Tax grew 15% to ₹1,056 crore. The company's profitability remained strong, reporting an EBITDA margin of 23% for Q4 FY 2026 and 26% for the full year. Key drivers included robust growth in US Generics and the India branded generic business significantly outperforming the Indian Pharmaceutical Market (IPM).

Key Highlights

1. 1

   Revenue from operations for Q4 FY 2026 increased by 21% year-on-year to ₹1,422 crore.

2. 2

   Profit after Tax (PAT) for Q4 FY 2026 grew by 18% to ₹267 crore.

3. 3

   For the full fiscal year 2026, Ajanta Pharma's revenue from operations rose by 17% to ₹5,453 crore.

4. 4

   Profit after Tax for FY 2026 also saw significant growth, increasing by 15% to ₹1,056 crore.

5. 5

   The company maintained a robust financial position for FY 2026, with Return on Capital Employed (ROCE) at 33% and Return on Net Worth (RONW) at 25%.

6. 6

   The US Generic segment demonstrated exceptional growth, with revenue up 56% in Q4 FY 2026 to ₹505 crore and a 49% increase for the full year to ₹1,557 crore.

7. 7

   Ajanta Pharma's India branded generic performance outpaced IPM growth by 33% as per IQVIA MAT March 2026, driven by new launches and volumes.